Needham reiterated coverage of Cooper with a rating of Buy and set a new price target of $99.00 from $100.00 previously
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/5/2026 | $101.00 → $86.00 | Buy | Needham |
| 3/4/2026 | $85.00 | Buy → Neutral | Rothschild & Co Redburn |
| 2/3/2026 | $100.00 → $99.00 | Buy | Needham |
| 11/13/2025 | $72.00 | Overweight → Equal Weight | Wells Fargo |
| 10/13/2025 | $85.00 | Overweight | Barclays |
| 10/1/2025 | $64.00 | Sell | Goldman |
| 8/28/2025 | $72.00 | Buy → Neutral | Citigroup |
| 7/22/2025 | $92.00 | Neutral → Outperform | BNP Paribas Exane |
4 - COOPER COMPANIES, INC. (0000711404) (Issuer)
3 - COOPER COMPANIES, INC. (0000711404) (Issuer)
4 - COOPER COMPANIES, INC. (0000711404) (Issuer)
4 - COOPER COMPANIES, INC. (0000711404) (Issuer)
4 - COOPER COMPANIES, INC. (0000711404) (Issuer)
4 - COOPER COMPANIES, INC. (0000711404) (Issuer)
CooperSurgical, a global leader in women’s health and fertility, today announced its support for Saving Mothers, a nonprofit organization dedicated to reducing maternal morbidity and mortality worldwide through innovative, scalable solutions. Founded by Taraneh Shirazian, MD, (@drshirazian) Saving Mothers focuses on improving maternal health outcomes by addressing critical gaps in care, education, and access to life-saving interventions. Dr. Shirazian is a practicing gynecologic surgeon, associate professor at NYU Langone Medical Center, and director of the Center for Fibroid care. "Saving Mothers commits to ensuring women everywhere have access to the care they need to survive and thri
SAN RAMON, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading global medical device company, released today its 2025 Corporate Sustainability Report. The report showcases the company’s commitment to people and planet, supported by expanded performance metrics and continued progress on sustainability priorities. A key milestone in this year’s report is the company’s first-time disclosure of Scope 3 greenhouse gas emissions, enhancing transparency and strengthening its sustainability reporting. "These achievements are the direct result of our global team’s partnership, innovation, and dedication to the customers and patients we serve," said Al White, CooperCom
SAN RAMON, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading global medical device company, today announced financial results for its fiscal second quarter ended April 30, 2026. Second quarter 2026 revenue of $1.082 billion, up 8%, or up 5% organically, from last year's second quarter.Second quarter 2026 GAAP diluted earnings per share (EPS) of $(0.40), down $0.84 from last year's second quarter driven by a litigation-related charge to resolve outstanding claims associated with a December 2023 voluntary product recall at CooperSurgical.Second quarter 2026 Non-GAAP diluted EPS of $1.21, up $0.25 or 26% from last year's second quarter. See "Reconciliation of
Needham reiterated coverage of Cooper with a rating of Buy and set a new price target of $86.00 from $101.00 previously
Rothschild & Co Redburn downgraded Cooper from Buy to Neutral and set a new price target of $85.00
Needham reiterated coverage of Cooper with a rating of Buy and set a new price target of $99.00 from $100.00 previously
10-Q - COOPER COMPANIES, INC. (0000711404) (Filer)
8-K - COOPER COMPANIES, INC. (0000711404) (Filer)
SD - COOPER COMPANIES, INC. (0000711404) (Filer)
SAN RAMON, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading global medical device company, today announced financial results for its fiscal second quarter ended April 30, 2026. Second quarter 2026 revenue of $1.082 billion, up 8%, or up 5% organically, from last year's second quarter.Second quarter 2026 GAAP diluted earnings per share (EPS) of $(0.40), down $0.84 from last year's second quarter driven by a litigation-related charge to resolve outstanding claims associated with a December 2023 voluntary product recall at CooperSurgical.Second quarter 2026 Non-GAAP diluted EPS of $1.21, up $0.25 or 26% from last year's second quarter. See "Reconciliation of
SAN RAMON, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading global medical device company, announced today it will report second quarter 2026 financial results on Thursday, June 4, 2026, at 4:15 PM ET. Following the release, the Company will host a conference call at 5:00 PM ET to discuss the results and current corporate developments. The dial-in number for the call is 800-715-9871 and the conference ID is 6529381. A simultaneous audio webcast and subsequent replay can be accessed at www.investor.coopercos.com About CooperCompanies CooperCompanies (NASDAQ:COO) is a leading global medical device company focused on helping people experience life's beauti
SAN RAMON, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading global medical device company, today announced financial results for its fiscal first quarter ended January 31, 2026. First quarter 2026 revenue of $1.024 billion, up 6%, or up 3% organically, from last year's first quarter.First quarter 2026 GAAP diluted earnings per share (EPS) of $0.66, up $0.14 or 27% from last year's first quarter.First quarter 2026 Non-GAAP diluted EPS of $1.10, up $0.18 or 20% from last year's first quarter. See "Reconciliation of Selected GAAP Results to Non-GAAP Results" below. "We're pleased to report a strong start to the fiscal year, highlighted by product launches,
SAN RAMON, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading global medical device company, announced today that its Board of Directors has appointed Paul Keel as an independent director, effective July 1, 2026. Mr. Keel has also been appointed to serve on the Audit Committee when he joins the Board. "We are delighted to welcome Paul to our Board as a new Director," said Colleen Jay, Chair of the Board of CooperCompanies. "His experience as a CEO in the medical device sector, along with a successful track record of leading complex global operations, will be a significant asset as Cooper continues to execute its strategy and create long-term value for patient
SAN RAMON, Calif., Dec. 23, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading medical device company, announced today that the Company's Board of Directors (the "Board") has appointed Walter (Walt) M Rosebrough, Jr. as an independent director, effective as of January 3, 2026. In connection with this appointment, the Company also has entered into a cooperation agreement (the "Cooperation Agreement") with Browning West, LP. ("Browning West"). Mr. Rosebrough will join the Board's Corporate Governance & Nominating Committee. The Board has also agreed that, by the end of 2026, it shall provide due and serious consideration for Mr. Rosebrough to be appointed Chair of the Board. In
Cooper's Lack of Strategic Focus, Misaligned Incentives, and Inadequate Board Oversight Have Led to Meaningful Underperformance Current Corporate Structure Obscures Value of Both CooperVision and CooperSurgical; Refocus as a Pure Play Vision Care Company Under a Refreshed Board May Lead to More Than a Doubling of Cooper's Stock Price Urges Cooper's Board to Appoint Browning West's Highly Skilled Director Candidates Who Will Improve the Company's Operating Plans Including Capital Allocation, Overhaul Management Incentives, and Evaluate Strategic Alternatives for CooperSurgical LOS ANGELES, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Browning West, LP ("Browning West", "us", or "we"), an investment
SC 13G/A - COOPER COMPANIES, INC. (0000711404) (Subject)
SC 13G - COOPER COMPANIES, INC. (0000711404) (Subject)
SC 13G/A - COOPER COMPANIES, INC. (0000711404) (Subject)